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Abstract
Bacteria regulate genes to survive antibiotic stress, but regulation can be far from perfect. When regulation is not
optimal, mutations that change gene expression can contribute to antibiotic resistance. It is not systematically under-
stood to what extent natural gene regulation is or is not optimal for distinct antibiotics, and how changes in expression of
specific genes quantitatively affect antibiotic resistance. Here we discover a simple quantitative relation between fitness,
gene expression, and antibiotic potency, which rationalizes our observation that a multitude of genes and even innate
antibiotic defense mechanisms have expression that is critically nonoptimal under antibiotic treatment. First, we devel-
oped a pooled-strain drug-diffusion assay and screened Escherichia coli overexpression and knockout libraries, finding
that resistance to a range of 31 antibiotics could result from changing expression of a large and functionally diverse set of
genes, in a primarily but not exclusively drug-specific manner. Second, by synthetically controlling the expression of
single-drug and multidrug resistance genes, we observed that their fitness–expression functions changed dramatically
under antibiotic treatment in accordance with a log-sensitivity relation. Thus, because many genes are nonoptimally
expressed under antibiotic treatment, many regulatory mutations can contribute to resistance by altering expression and
by activating latent defenses.
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Introduction
Regulation of gene expression contributes to the ability of
bacteria to survive antibiotics and other stresses (Miller and
Sulavik 1996; Grkovic et al. 2002; Depardieu et al. 2007;
Gooderham and Hancock 2009; Lister et al. 2009; Storz and
Hengge 2010; Poole 2012). However, regulation is rarely per-
fect (Price et al. 2013); some genes important for survival may
not be regulated by a given stress and even if they are regu-
lated their stress-induced expression levels may not be best
tuned to maximize growth and survival under the stress
(Bollenbach et al. 2009). The defining feature of nonoptimal-
ity is the potential for improvement; a gene is nonoptimally
expressed under stress if mutations that change its expression
level can improve the ability to survive the stress. Thus, muta-
tions that confer antibiotic resistance by changing or disrupt-
ing regulation can be understood as instances where the
natural gene expression level, though possibly optimal in nat-
ural environments, is nonoptimal under antibiotic treatment.
Many cases are known where resistance results from muta-
tions that change gene expression, but the extent of this
phenomenon has not been systematically characterized.
Mutations that confer resistance to antibiotics by altering
the expression of either native or horizontally transferred re-
sistance genes are common in clinical isolates and in labora-
tory evolution experiments (McCalla et al. 1978; Bergstrom
and Normark 1979; Curtis et al. 1985; Flensburg and Skold
1987; Maneewannakul and Levy 1996; Koutsolioutsou et al.
2005; Depardieu et al. 2007). These genes have included those
with specific functions in antibiotic resistance, such as drug
degrading enzymes (e.g., beta-lactamases) and transcriptional
regulators of stress response (e.g., marA and soxS), and also
those not thought of as “resistance genes” per se but genes
whose function is intrinsic to a drug’s mechanism of action,
including drug targets themselves (e.g., DHFR, known in
Escherichia coli as folA), enzymes that activate a prodrug
(e.g., nfsA), and porins that mediate cellular entry of certain
antibiotic molecules (e.g., ompF). Nonoptimal regulation can
also be identified in chemical-genetic screens where gene
deletion or overexpression libraries are tested for resistance
to different antibiotics. Several large-scale screens of gene
deletion libraries have been applied to stresses at subinhibi-
tory intensities to identify hypersensitivity, rather than resis-
tance, to identify a cell’s “intrinsic resistome” (Tamae et al.
2008), and to understand drug mode of action and gene
function (Hillenmeyer et al. 2008; Girgis et al. 2009; Liu et al.
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2010; Nichols et al. 2011; Lee et al. 2014; French et al. 2016;
Shiver et al. 2016). However, any given gene in the intrinsic
resistome may or may not have the capacity to contribute to
the evolution of stronger levels of antibiotic resistance, which
means that genetic screens for hypersensitivity (with drug
concentrations below the wild type’s minimum inhibitory
concentration, MIC) do not provide the same information
as screens for resistance (testing drug concentrations above
the MIC). Screens above the MIC have been applied to gene
overexpression mutants and have typically applied a stringent
selection (far above the MIC) to identify only the few most
highly resistant mutants, often in search of drug target genes
(Li et al. 2004; Pathania et al. 2009; Soo et al. 2011; Farha and
Brown 2016). Because previous array-based methods are labor
intensive (Breidenstein et al. 2008; Schurek et al. 2008;
Fernandez et al. 2013), and the results of such screens depend
on drug concentration with an informative concentration
range that is highly variable between different drugs
(French et al. 2016), we have been lacking an efficient and
sensitive screen for nonoptimally expressed genes under an-
tibiotic treatment.
Central to understanding the optimality of expression is
how protein levels affect fitness, which is understood to be
through a sum of benefits and costs of expression (Dekel and
Alon 2005). Experimental evolution has shown that expres-
sion levels can rapidly evolve to the optimal solution of the
fitness–expression function in a given environment, and thus
this framework can produce predictive relationships between
environments and optimal gene expression levels (Dekel and
Alon 2005).
Therefore, to understand how hidden potential for antibi-
otic resistance is unrealized by a cell’s native regulatory pro-
gram, we sought to investigate both how widespread is
nonoptimal gene expression across a range of antibiotic
mechanisms and how antibiotics change fitness–expression
functions.
Results
A Rapid Genome-Wide Screen for Nonoptimal Gene
Expression under Antibiotic Treatment
We developed a robust, rapid, and inexpensive genome-wide
screen to identify nonoptimally expressed genes, that is, genes
where a change in expression confers drug resistance. To
identify both negative and positive expression changes that
confer resistance, we screened two E. coli strain libraries: A
gene deletion library (in which each nonessential gene is in-
dividually replaced by a Kanamycin resistance cassette) (Baba
et al. 2006) and a gene overexpression library (a collection of
plasmid-encoded isopropyl b-D-1-thiogalactopyranoside
[IPTG]-inducible genes) (Kitagawa et al. 2005). The overex-
pression library was first transformed in pools into a wild-type
MG1655 DlacZYA, conferring the favorable feature that each
expression mutant is represented in the screen by the
descendants of hundreds of unique transformation events.
The libraries were screened on an antibiotic diffusion gradi-
ent, avoiding the need to fine tune the concentration of each
drug and providing the sensitivity to detect both strongly and
mildly resistant mutants. The assay comprises two steps
(fig. 1a): 1) A strain library (deletion or overexpression) is
pooled and seeded as a lawn onto a nutrient agar plate. An
aliquot of concentrated antibiotic solution is spotted in the
center of the plate, as in a classical disk-diffusion assay, and
diffuses through the media forming a gradient of antibiotic
concentrations. Following incubation, all strains with the
wild-type resistance level grow into a dense lawn across the
plate, except in a zone of clearing around the antibiotic spot,
where drug concentrations are high enough to preclude vis-
ible growth. However, strains with enhanced resistance to the
antibiotic grow at higher drug concentrations, closer to the
drug spot, and thus appear as visible individual colonies inside
the zone of inhibition. By selecting on solid agar the popula-
tion of survivors is spatially separated, preventing the most
resistant mutants from outcompeting slower-growing
mutants of interest. 2) Drug-resistant colonies are picked
and identified by Sanger sequencing of the expression plasmid
or of the chromosome adjacent to the site of gene deletion.
When the deletion or overexpression of a gene improves drug
resistance, the gene is identified as having nonoptimally high
or nonoptimally low expression, respectively, under antibiotic
treatment.
We employed our assay on 31 antibiotics, representing
most classes of antibiotics used in the treatment of Gram-
negative bacteria (table 1), and observed many gene expres-
sion mutants providing resistance. For each of three expres-
sion conditions per antibiotic (deletion; mild overexpression,
15mM IPTG; strong overexpression, 150mM IPTG), a pooled
diffusion screen was performed and 48 colonies were picked
from inside the wild-type zone of inhibition and sequenced.
The presence and abundance of drug-resistant gene expres-
sion mutants is highly variable across antibiotics, with very
strongly resistant mutants appearing on some drugs (e.g.,
penicillin G and trimethoprim), while other antibiotics per-
mitted no resistant expression mutants at all (e.g., colistin)
(fig. 1b, supplementary fig. S1, Supplementary Material on-
line). In contrast, plates inoculated with clonal wild-type cul-
tures rarely show colonies in the zone of inhibition,
representing infrequent spontaneous drug resistance muta-
tions. The quantitative level of resistance, as measured by how
far into the zone of inhibition colonies extended, was also
highly variable across antibiotics, with gene overexpression
commonly but not always capable of producing stronger re-
sistance than gene deletion (supplementary fig. S2,
Supplementary Material online). Colonies that grew the
very farthest into zones of inhibition were cases of known,
potent resistance determinants that have direct physical
interactions with drugs or regulate directly interacting genes
(folA, ampC, marA, and soxS). Over half of the 93 assays (31
drugs 3 expression conditions) produced resistant colonies,
for a total of approximately 2,400 colonies picked and se-
quenced. To avoid false identifications from the occurrence
of spontaneous resistance mutations, we called gene–drug
interactions only for genes that were detected in at least
two separate colonies in the zone of clearing of the same
antibiotic (average false discovery rate <1%, see supplemen-
tary note, Supplementary Material online). The robustness of
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the primary screen was tested for all genes identified in three
drugs of different mode of action (clindamycin, sulfamethox-
azole, and phleomycin), which together interacted with 28%
of all hits. The drug diffusion screen was repeated for each hit
using wild-type cultures inoculated with a 1:500 fraction of
the mutant strain, where four drug-resistant colonies per as-
say plate were picked and tested for presence of the mutation
(see Materials and Methods). This secondary validation con-
firmed the resistant phenotype for 34 of 37 genes tested, most
often with 3/4 or 4/4 colonies picked being the inoculated
mutant, conferring extremely high statistical significance
(P< 107 given the initial mutant: wild-type ratio of 1:500)
(supplementary table S2, Supplementary Material online).
Novel and Functionally Diverse Pathways to Drug
Resistance
For the majority of antibiotics tested, the screens revealed
many pathways to resistance through gene expression
changes. Sequencing approximately 2,400 drug resistant col-
onies identified over 200 gene–drug interactions where
changing a gene’s expression level was repeatedly observed
FIG. 1. A genome-wide screen identifies changes in gene expression that confer antibiotic resistance. (a) A library of Escherichia coli strains with
genes deleted or overexpressed is pooled and plated as a lawn on agar. A drug spot is applied which creates a zone of growth inhibition. Members of
the strain library with increased drug resistance grow inside the zone of inhibition (yellow colonies), and are picked and identified by DNA
sequencing. (b) Photographs of assay plates for five example antibiotics (out of 31) illustrate that both gene deletion and overexpression can confer
drug resistance, and the possible levels of resistance range from none at all (e.g., colistin), to modest (e.g., clindamycin, vancomycin), to very strong
(e.g., penicillin, trimethoprim). Plate images for all antibiotics are shown in supplementary figure S1, Supplementary Material online.
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to increase resistance to an antibiotic (1,900 colonies with
repeatedly observed interactions, 500 colonies with single-
instance interactions; see supplementary table S1 and supple-
mentary note, Supplementary Material online, for antibiotic-
specific numbers. Statistical resampling indicated that for
many antibiotics the number of gene–drug interactions iden-
tified had saturated at this level of sampling, but under some
antibiotic treatments the number of nonoptimally expressed
genes is likely to be greater still; supplementary fig. S3,
Supplementary Material online). These changes in gene ex-
pression consisted of both overexpression and deletion (59%
and 41% of genes, respectively; fig. 2a), and most conferred
resistance to a single class of drug (93%). The majority of the
genes identified have not been previously related to drug
resistance to the best of our knowledge (83%, including 34
unannotated genes and 52 annotated with unrelated func-
tions). When these genes were compared with screens for
resistance to a variety of nonclinical toxins, we observed a
statistically significant enrichment for the recall of genes pre-
viously associated with multistress resistance or large
increases in MIC (supplementary fig. S4, Supplementary
Material online) (Hirakawa et al. 2003; Soo et al. 2011). We
also compared these results with previously reported tran-
scriptional changes in E. coli strains that have evolved resis-
tance in the laboratory (Suzuki et al. 2014), which revealed
that our overexpression hits were significantly more likely to
be upregulated than other genes in evolved drug resistant E.
coli (P< 106), and deletion hits were significantly more likely
to be downregulated in drug resistant E. coli (P< 0.03) (sup-
plementary fig. S4, Supplementary Material online).
We detected multiple genes involved in the metabolism
and transport of lipopolysaccharide, enterobactin, poly-
amines, and ubiquinone, suggesting that changes in the reg-
ulation of these molecules can contribute to resistance to
specific antibiotics. Genes with annotation that suggested a
relation to drug action encoded diverse functions, including
modification of the cellular process affected by a drug (such as
sbmC which inhibits DNA Gyrase and resists DNA-damaging
drugs [Baquero et al. 1995; Nakanishi et al. 1998; Oh et al.
2001; Chatterji and Nagaraja 2002]), modification of cell per-
meability (such as ompF which facilitates entry of beta-lactam
antibiotics into the cell [Nikaido 1989]), chemical modifica-
tion of drugs (such as ampC which degrades beta-lactam
antibiotics [Bergstrom and Normark 1979]), the activation
of efflux and acid resistance systems (such as marA and
soxS which confer multidrug resistance by transcriptional ac-
tivation of drug efflux systems [Alekshun and Levy 1999;
Martin and Rosner 2002]), and increased flux through a
drug-inhibited pathway (such as nudB, which catalyzes the
first committed step in folate biosynthesis [Suzuki and Brown
1974], resisting folate synthesis inhibitors) (fig. 2b; supplemen-
tary table S3, Supplementary Material online).
In every class of antibiotic, except cell-membrane-targeting
drugs, many of these different modes of resistance were ob-
served (fig. 2b). Even within general modes of resistance a
remarkable diversity of mechanisms was observed. For exam-
ple, four different strategies could increase pathway flux to
resist folate synthesis inhibition: 1) Overproduction of a drug’s
target enzyme (folA), 2) overproduction of a drug-insensitive
replacement enzyme (folM), 3) overproduction of an up-
stream enzyme that controls total incoming flux (nudB),
and 4) loss of enzymes that convert pathway metabolites
to alternate products (DfolX, DfolM; note that folM can be
overexpressed to resist trimethoprim or deleted to resist sul-
fonamides; supplementary tables S1 and S2, Supplementary
Material online).
Nine genes were identified whose overexpression increased
resistance to multiple antibiotics with diverse mechanisms.
Together with the known multidrug resistance genes marA
and soxS (Alekshun and Levy 1999; Martin and Rosner 2002),
seven novel multidrug resistance genes of varied functions
were identified. These include gadW, a transcriptional regu-
lator of acid resistance; bssR, a regulator of biofilm; and ddpF, a
putative component of an ABC transporter. The functional
annotations of the remaining four multidrug resistance genes
(hemD, yhbT, gmr, and rbsR; see supplementary table S1,
Supplementary Material online) do not immediately suggest
mechanisms of resistance.
Table 1. List of Antibiotics Used in This Study, Mechanism of Action,
and Abbreviation.
Drug Class Drug Name Abbreviation
Cell wall synthesis
Cephalosporin Cephalexin CLX
Cefoxitin FOX
Cefsulodin CFS
Glycopeptide Vancomycin VAN
Penicillin Ampicillin AMP
Carbenicillin CRB
Mecillinam MEC
Penicillin G PEN
Cell membrane
Polypeptide Colistin COL
Polymyxin B PMB
Fatty acid synthesis inhibitor Triclosan TCL
Transcription
Rifamycin Rifamycin SV RIF
Translation
Aminoglycoside Amikacin AMK
Streptomycin STR
Tobramycin TOB
Macrolide Azithromycin AZI
Erythromycin ERY
Spectinomycin SPX
Spiramycin SPR
Lincosamide Clindamycin CLI
Tetracycline Doxycycline DOX
Tetracycline TET
DNA synthesis
Quinolone Ciprofloxacin CPR
Lomefloxacin LOM
Nalidixic acid NAL
Folate synthesis inhibitor Trimethoprim TMP
Sulfacetamide SCM
Sulfamethoxazole SMX
Free radical production
Glycopeptide Bleomycin BLM
Phleomycin PHM
Nitrofuran Nitrofurantoin NIT
Palmer et al. . doi:10.1093/molbev/msy163 MBE
4
D
ow
nloaded from
 https://academ
ic.oup.com
/m
be/advance-article-abstract/doi/10.1093/m
olbev/m
sy163/5085501 by Institute of Science and Technology Austria user on 28 Septem
ber 2018
FIG. 2. Drug-specific and drug-general resistance through a multitude of gene expression changes. (a) Antibiotics (black hexagons) are grouped by
mechanism of action (see table 1 for abbreviations). Escherichia coli genes are marked by red circles when deletion confers antibiotic resistance and
blue circles when overexpression confers antibiotic resistance; known antibiotic targets whose overexpression confers resistance are outlined in
dark blue. Changes in gene expression that resist only one mechanism of drug action are grouped around the antibiotics of that mechanism, while
those that resist multiple classes of drug are shown in the center. Pale-colored links denote changes in gene expression that were identified only
once as resisting a particular drug, that are included because they were repeatedly observed to resist another drug of the same mechanism of action
(supplementary note, Supplementary Material online). Supplementary table S1, Supplementary Material online, lists all gene–drug interactions.
(b) Changes in gene expression can confer drug resistance through a wide variety of mechanisms. Some of the identified genes have functional
annotations that clearly suggest a mechanism of resistance (supplementary table S3, Supplementary Material online), while most currently lack
functional annotation (25% of genes) or do not have a functional annotation related to antibiotic action (38% of genes).
Nonoptimal Gene Expression Under Drug Treatment . doi:10.1093/molbev/msy163 MBE
5
D
ow
nloaded from
 https://academ
ic.oup.com
/m
be/advance-article-abstract/doi/10.1093/m
olbev/m
sy163/5085501 by Institute of Science and Technology Austria user on 28 Septem
ber 2018
Overexpression of antibiotic targets was found to confer
resistance only in specific antibiotic classes. Genes encoding
specific targets of drugs are of particular interest because if an
antibiotic acts by inhibiting target activity, target upregulation
or amplification may confer drug resistance; additionally, evo-
lution may then act on a larger number of gene templates to
drive the evolution of greater resistance (Andersson and
Hughes 2009). However, in only 4 of 31 antibiotics was
drug target overexpression observed to confer resistance.
Most of these common Gram-negative antibiotics do not
act on a single target gene, instead inhibiting a multiprotein
complex, a family of related enzymes, or acting on a non-
protein target such as the cell membrane. Yet, target over-
expression does not always confer resistance even for drugs
with a single protein target, a result that is explained by recent
research showing that target overexpression fails to confer
resistance in two cases: First, for drugs that induce harmful
target-catalyzed reactions, such as sulfonamides and quino-
lones, and second, for genes where overexpression alone
incurs severe fitness costs, as is often observed for the targets
of penicillins and cephalosporins (Meisel et al. 2003; Legaree
et al. 2007; Palmer and Kishony 2014) (supplementary table
S4, Supplementary Material online). Because drug–target
interactions are often absent, and because the abundance
of nonoptimal gene expression creates many expression-
resistance interactions that do not represent drug targets,
only a very small fraction of all expression-mediated paths
to resistance represent target–drug interactions. For this rea-
son, methods to identify a novel drug’s molecular target by
screening for overexpression-mediated resistance, and possi-
bly also knockdown-mediated sensitivity, may often be con-
founded by nonoptimal gene expression. This is supported by
the frequent observation that resistance can result from ex-
pression changes in many nontarget enzymes in the target
pathway or closely related pathways, and is best exemplified
by sulfonamides, where resistance can develop from changes
in the expression of enzymes both upstream and down-
stream of the target, but not the target itself.
The absence of a few known resistance mechanisms sug-
gests limitations of these strain libraries. No components of
the acrAB-tolC multidrug efflux pump were identified, likely
because overexpression of a single component is alone unable
to increase resistance. Loss-of-function mutations in marR, a
repressor of marA, were also not observed here though they
are known to confer multidrug resistance (Ariza et al. 1994;
Toprak et al. 2012). This is likely due to a polar effect arising
from the position of marR upstream of marA in a polycis-
tronic operon, such that replacement of marR by a
Kanamycin resistance cassette in the deletion library
obstructs marA transcription. The mechanisms behind these
known absences may be present more widely, suggesting that
the present data set underestimates the number of genes that
are nonoptimally expressed under antibiotic treatment.
Antibiotics Perturb Fitness Functions according to a
Log-Sensitivity Relation
The optimal expression levels of genes can dramatically shift
under antibiotic treatment. The fitness effects of gene
expression are composed of fitness benefits and costs of ex-
pression, which combine to generate a fitness versus expres-
sion function that is typically concave (because with
increasing expression, benefits saturate and costs intensify)
(Dekel and Alon 2005). The observation that changing the
expression level of a gene can increase growth rate in the
presence of antibiotics suggests that this fitness–expression
function is maximized at different expression levels in drug-
free compared with drug-treated environments. To directly
observe how these fitness–expression functions are altered by
antibiotics, we constructed experimentally controlled expres-
sion strains in which the gene of interest is deleted from the
chromosome and resupplied on a plasmid under IPTG regu-
lation (an empty plasmid was used for zero expression). The
relationship between IPTG and transcription of a plasmid-
borne gene was quantified using a lacZ reporter gene (note
that the host strain is DlacZYA), revealing a monotonic rela-
tionship over IPTG doses up to 200mM (supplementary fig.
S5, Supplementary Material online), and furthermore this ex-
pression system was previously determined to behave ro-
bustly under partially inhibitory doses of mechanistically
diverse antibiotics (Palmer and Kishony 2014).
We examined the ampC–ampicillin and nfsA–nitrofuran-
toin interactions as examples of overexpression- and deletion-
mediated drug resistance. At fixed drug concentrations, bac-
terial growth rates were measured across IPTG gradients using
a sensitive bioluminescence assay (Kishony and Leibler 2003).
In the absence of drug, the costs and benefits of expressing
these genes affect growth by only a few percent (fig. 3a).
Indeed most genes in E. coli, including the majority of those
identified here as nonoptimally expressed under drug treat-
ment, have only modest effects on fitness when either deleted
or strongly overexpressed (supplementary fig. S6,
Supplementary Material online). However, as drug toxicity
approaches lethal levels, expression levels that were optimal
in the absence of drug become lethally nonoptimal in its
presence, and the fitness–expression function is dominated
by the effect of gene expression on drug susceptibility (fig. 3b).
These fitness landscapes are quantitatively explained by a
simple model with a single parameter that relates gene ex-
pression to antibiotic potency. Bacterial fitness is modeled as
the product of two functions: fG is the effect of gene expres-
sion level g (considered in the absence of antibiotics), and fA is
the dose–response to antibiotic concentration a (considered
at wild-type gene expression gwt), thus Fitness(g, a) ¼
fG(g).fA(a). The gene–antibiotic interaction is introduced by
a “log-sensitivity” g (also known as elasticity) whereby an x-
fold change in gene expression causes an xg-fold change in
antibiotic potency, so a becomes a.(g/gwt)
g, and thus
Fitness(g, a) ¼ fG(g).fA(a.(g/gwt)g). This model defines family
of fitness landscapes depending on fG and fA, which can be
experimentally measured, and a single free parameter g that
quantifies interaction strength and sign (fig. 3c). Log-
sensitivity g is modeled as being constant in the neighbor-
hood of wild-type expression (fig. 3c, blue lines are straight),
though sensitivity is likely to saturate (g!0) at very small and
very large expression levels (far left and far right in fig. 3c).
How far this relationship holds constant may depend on the
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FIG. 3. Antibiotic treatment alters optimal levels of gene expression. (a, b) Escherichia coli strains were constructed with experimentally controlled
expression of nfsA or ampC, by deleting the respective gene from the chromosome and resupplying by plasmid an IPTG-inducible copy; zero
expression was achieved with an empty plasmid (MU ¼ Miller Units, quantified by LacZ assay; supplementary fig. S5, Supplementary Material
online). Growth rates were measured as a function of gene expression using a sensitive bioluminescence assay (error bars are 95% confidence limits;
n¼ 5 for nfsA, n¼ 10 for ampC). For each gene, growth is optimized in a particular expression range (gray shading). Fitness–expression functions
were measured again at different doses of antibiotics that interact with these genes (nitrofurantoin–nfsA; ampicillin–ampC), revealing that
antibiotic treatment shifts these functions so dramatically that expression levels which are optimal in the absence of antibiotic become lethally
Nonoptimal Gene Expression Under Drug Treatment . doi:10.1093/molbev/msy163 MBE
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nature of interaction: Enzymes that physically interact with a
drug (e.g., trimethoprim and its target folA) can have constant
sensitivity over a 100-fold range (Palmer and Kishony 2014),
whereas an indirect regulatory effect, such as from a tran-
scription factor, may saturate as soon as regulation of target
genes saturates. Supplementary code, Supplementary
Material online, is provided to implement this model. This
simple model makes two predictions: First, for any gene
whose expression level modifies the effective concentration
of a toxin (i.e., whenever g 6¼ 0), exposure to that toxin will
change the optimal expression level of that gene; second, the
expression level of such genes can have life-or-death conse-
quences in the presence of the toxin, even if their expression
level has only minor effects on fitness in the absence of stress.
Together, these predictions explain why far from optimum
gene expression is common under antibiotic treatment.
Applying this model to experimentally measured fitness func-
tions fG and dose–responses fA produces remarkably accurate
matches to the observed interaction landscapes of ampC–
ampicillin (at g ¼ –1) and nfsA–nitrofurantoin (at g ¼
þ0.25) (fig. 3d and e). This model will not be precise in
situations where g is not constant or where fitness is not as
simple as the product of fG and fA, but the general predictions
are robust to quantitative deviations from these assumptions.
Yet, an antibiotic-induced change in the optimum gene ex-
pression level does not guarantee nonoptimality, because
natural regulatory systems may adaptively adjust expression
under antibiotic treatment. We next investigated how well
native regulation uses the potential for resistance in several
examples of potent drug resistance genes.
Drug Resistance Systems Are Often Poorly Utilized
When a change in gene expression has the potential to confer
antibiotic resistance, wild-type regulation might be using all, a
fraction of, or none of this potential for resistance. To explore
this, we focused on two strong drug-specific resistance genes,
ampC and sbmC, and the two most broadly protective multi-
drug resistance genes, marA and soxS. To understand how
well these drug resistance genes are natively utilized, we quan-
tified to what extent wild-type resistance exceeds the resis-
tance without the gene and how closely it approaches the
maximum resistance at optimal gene expression. The maxi-
mal resistance was determined by constructing experimen-
tally controlled expression strains and measuring their growth
on 2D antibiotic-IPTG gradients in microtiter plates (as above,
an empty plasmid was used for zero expression; fig. 4).
Wild-type regulation of the genes we tested was occasion-
ally adequate, but in most cases achieved only a small fraction
of the potential for resistance. Under treatment by either a
penicillin or a cephalosporin, we observe that wild-type ampC
expression levels provide negligible resistance relative to a
DampC strain, despite the potential to confer 100-fold resis-
tance when overexpressed (fig. 4b, supplementary fig. S7b,
Supplementary Material online). Similarly, wild-type regula-
tion of sbmC realizes only a small fraction of the potential for
phleomycin resistance (fig. 4c, supplementary fig. S7b,
Supplementary Material online). Expression of marA and
soxS can confer resistance to several different antibiotics
(fig. 4d and e). This potential for resistance is reasonably
well used by the wild-type strain in the case of clindamycin
(marA and soxS) and trimethoprim (soxS only) (unexpect-
edly, both synthetic antibiotics) but is poorly utilized in all
other cases (fig. 4d and e; supplementary fig. S7a,
Supplementary Material online). Past observations that acti-
vating mutations in the mar and sox operons confer multi-
drug resistance in clinical isolates is evidence that these
systems are also poorly utilized during clinical treatment of
E. coli infections, and thereby that the nonoptimality ob-
served here is not an artifact of laboratory growth
(Maneewannakul and Levy 1996; Koutsolioutsou et al.
2005). The observation here that some antibiotics trigger in-
nate defenses and some do not has two implications. First, it
affects the interpretation of genetic studies of drug resistance:
If a mutation that changes a gene’s expression level confers
resistance to drug A but not drug B, this does not necessarily
mean the gene is only involved in drug A resistance, for it may
simply have close to optimal regulation under drug B so that
further mutational change is unhelpful. Second, it suggests
that future study of the mechanistic or chemical determi-
nants of this variation may be useful in designing antibiotics
which preserve their efficacy by not inducing innate resistance
mechanisms.
In summary, some but not all antibiotics could potentially
be resisted by intrinsic stress response systems, and therefore
these antibiotics are effective—at least before regulatory
mutations arise—because native regulation does not fully
employ those defenses.
The “Intrinsic” Resistome Is Different from the
“Latent” Resistome
Our results suggest that resistance determinants can be clas-
sified into two categories (fig. 5a). The first category is the
intrinsic resistome, which is revealed by drug hypersensitivity
FIG. 3. Continued
nonoptimal at high antibiotic concentrations. (c) A general model of how gene–drug interactions affect fitness is built from three parts: 1) fG is the
fitness effect of gene expression level g, 2) fA is the fitness effect of antibiotic concentration a, and 3) gene–drug interaction is described by log-
sensitivity g, where each 1% increase in gene expression affects a g% change in apparent antibiotic potency. Fitness as a function of gene expression
and antibiotic dose is fG fA. In general, fG and fA can be empirically determined; here for illustration, we use functions that resemble experimental
observations: fG is quadratic, fA¼ 1 – a/K (K is a constant). For any log-sensitivity that substantially differs from zero (g –0.25 or gþ0.25), a
positive or negative change in gene expression can confer growth under antibiotic doses that are fully inhibitory when expression is at the
antibiotic-free optimum (gray-shaded region). a.u., arbitrary units. (d, e) The observed antibiotic-induced changes in optimum gene expression
levels for nfsA and ampC are quantitatively described by this model when using the measured relationships for fG and fA, with g¼þ0.25 for nfsA–
nitrofurantoin, and g ¼ –1 for ampC–ampicillin.
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FIG. 4. Intrinsic antibiotic resistance systems are often poorly utilized and hold unrealized potential for stronger resistance. (a) The optimality of a
gene’s response to antibiotic treatment was investigated by comparing the drug susceptibility of three Escherichia coli strains: One lacking the gene
(black), one with wild-type gene regulation (blue), and one where susceptibility can be measured over a range of experimentally controlled gene
expression levels (red). (b) ampC encodes a potent beta-lactamase: Overexpression can confer a 100-fold increase in resistance to penicillins or
cephalosporins. However, with wild-type regulation of ampC (blue) almost none of this potential for resistance (red) is used. Right: An empirical
fitness landscape shows the growth inhibitory effect of an antibiotic at different levels of gene expression. Inhibition of the wild-type strain is
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of gene knockout mutants (Tamae et al. 2008; Nichols et al.
2011). Here intrinsic means not only that the genes are pre-
sent in the genome, but are functional: These genes make a
measurable contribution to drug resistance at their native
expression levels, whether or not it is optimal. The second
category of resistance determinants contains genes where a
change from native expression increases drug resistance.
These genes must have been nonoptimally expressed under
drug treatment, and can be considered the latent resistome.
This group exists not only because resistance genes that di-
rectly protect against drug stress are often nonoptimally
expressed, but also because any gene with nonoptimal ex-
pression under drug stress could manifest as a resistance gene.
This occurs simply because optimizing gene expression under
drug stress can improve survival; direct interaction with a
drug or drug-inhibited pathway is unnecessary. In principle
genes could belong to both the intrinsic and latent resistome,
if native expression confers some resistance that is less than
the maximum. However, comparing “latent resistance” genes
with previous screens for the intrinsic resistome suggests that
these categories have little overlap. Tamae et al. (2008) iden-
tified antibiotic-hypersensitive gene deletion mutants in E.
coli; comparing their findings in the case of antibiotics also
studied here reveals, as expected, that mutations are more
likely to be harmful than beneficial (the intrinsic resistome is
more populous than the latent resistome), and that it is rare
for a gene to belong to both groups (fig. 5b). Nichols et al.
(2011) measured the colony size of each E. coli gene deletion
mutant when grown in subinhibitory antibiotic doses. Of the
genes here identified to confer resistance to some antibiotic
when overexpressed, only in five cases does deletion of that
gene incur major growth defects when exposed to the same
antibiotic (fig. 5c). Similarly, comparison with a screen for the
intrinsic resistome by Girgis et al. (2009) identified only ampC
as a gene exhibiting both intrinsic and latent resistance. These
results emphasize the importance of the distinction between
intrinsic and latent drug resistance genes, which are identified
by different experimental designs and have different biological
meaning.
Discussion
An organism’s gene expression state, and gene regulatory
machinery, evolves to adapt to the environmental conditions
and perturbations that are regularly encountered in its ecolog-
ical niche. However, when an organism encounters a novel or
rare perturbation, the gene expression response may be far
from perfect (Kalisky et al. 2007). Our results show that for
nearly every antibiotic tested across diverse mechanisms, many
microbial genes are have nonoptimal expression under antibi-
otic treatment with life-or-death consequences. A simple
model was developed which allows the strength of a gene–
antibiotic interaction to be evaluated by its log-sensitivity,
which is independent of the size of a particular expression
change. This model showed that under antibiotic treatment,
even a weak linkage between gene expression and susceptibility
will overwhelm the typically modest fitness effects of expres-
sion level (supplementary fig. S6, Supplementary Material on-
line), such that changing expression away from the antibiotic-
free optimum improves resistance (fig. 3). This effect is pro-
duced even by weak interactions, which might explain why
gene expression changes in many aspects of bacterial physiol-
ogy, most with no apparent connection to drug mechanism,
can contribute to the evolution of antibiotic resistance (fig. 2b).
We anticipate that potential clinical relevance will lie in the
general phenomenon more so than in the specific mutations
identified here, for two reasons. First, the majority of mutations
have a magnitude of effect too small to individually confer
clinically significant resistance (supplementary figs. S1 and S2,
Supplementary Material online: most changes in zone of inhi-
bition are <5 mm). Second, genes that indirectly influence
drug susceptibility via an effect on cellular physiology may be
environment dependent in their effect. The clinical relevance of
numerous regulatory mutations contributing to drug resis-
tance, perhaps each to a modest degree, is demonstrated by
genome-sequencing of Mycobacterium tuberculosis isolates,
which has identified dozens of mutations in intergenic regions
and promoters that are each associated with antibiotic resis-
tance (Sandgren et al. 2009; Farhat et al. 2013; Zhang et al.
2013).
The impact of nonoptimal gene expression on antibiotic
susceptibility is variable between drugs. These differences can
be visualized in terms of how far into a zone of inhibition
drug-resistant colonies appear (fig. 1 and supplementary fig.
S1, Supplementary Material online). Gene expression is not
detectably nonoptimal under all clinically relevant antibiotics:
For example, we identified no changes in gene expression that
confer resistance to polymyxins. This does not imply that
every gene’s expression is precisely tuned, because optimality
merely means “as good as it gets,” and a functionally optimal
state occurs when drug resistance is insensitive to gene ex-
pression or is only worsened by any large change (fig. 5a, top
row). Some differences between drugs with similar mecha-
nisms may be the consequence of an experimental design
that emphasizes a low false discovery rate and therefore
FIG. 4. Continued
illustrated by a transparent blue surface across the landscape; regions where the landscape is above the blue surface are levels of gene expression
conferring antibiotic tolerance that is superior to wild type. A red line traces the gene expression response that maximizes growth at each drug
dose. (c) sbmC encodes a DNA gyrase inhibitor whose overexpression confers resistance to the DNA-damaging drug phleomycin. However, a wild-
type strain (blue) treated with phleomycin uses very little of the potential resistance offered by sbmC (red). (d, e) The use of soxS and marA was
examined under treatment by nine different antibiotics (cefsulodin, nitrofurantoin, and phleomycin are not shown because marA and soxS had no
effect on susceptibility; supplementary fig. S7, Supplementary Material online). For those drugs where experimental control of gene expression
(red) increased resistance relative to gene deletion (black), the wild-type strain (blue) most often used only a fraction of the potential for drug
resistance. Right: Selected examples of fitness landscapes of drug resistance versus marA expression. marA use is suboptimal in ampicillin and
ciprofloxacin, and in clindamycin marA is only used effectively when growth is inhibited by more than 50%.
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FIG. 5. Drug resistance genes can be latent and/or intrinsic, depending on the optimality of wild-type gene expression under drug treatment. (a)
The relationship between drug resistance and gene expression can take several different shapes, which illustrates a distinction between genes that
contribute to resistance at wild-type expression—the intrinsic resistome—and genes with the potential to contribute to resistance if their
expression is changed from wild type—the latent resistome. (b) The current screen for latent resistance genes (number of genes per antibiotic in
yellow) has little overlap (number in green) with a published screen of “intrinsic resistance genes” (number in blue) (Tamae et al. 2008). (c) For 86
gene–drug interactions where overexpression conferred antibiotic resistance, a deletion mutant of the same gene has previously been grown in a
subinhibitory dose of the same antibiotic and its colony size measured as a Z-score relative to the set of all viable gene deletion mutants in
Escherichia coli (Nichols et al. 2011). In this comparison, five genes were observed to confer both resistance when overexpressed and strong
hypersensitivity when deleted (green gene names). marA and soxS are not among these five, but show modest sensitivity to several antibiotics
when deleted (Z-scores  1 to 2).
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underestimates the number of true positives (supplementary
fig. S3, Supplementary Material online). This is likely to cause
an underestimation of the rate of cross-resistance conferred
by individual mutations. Additionally, bacteria that evolve
antibiotic resistance through the acquisition of multiple
mutations are more likely to exhibit multidrug resistance.
This is simply because with multiple mutations, there is a
greater probability that any one mutation confers multidrug
resistance, as has been observed in experimental directed
evolution of antibiotic resistance (Toprak et al. 2012; Lazar
et al. 2014).
Individual genes can show variable degrees of nonoptimal-
ity in different antibiotics. Multidrug resistance genes marA
and sox have close to optimal induction in some drugs (e.g.,
Clindamycin) and far from optimal induction in others (e.g.,
Ciprofloxacin). Therefore the magnitude of resistance gained
by marA overexpression is not only a property of how well
the system protects against a given drug, but is strongly de-
termined by the optimality or otherwise of wild-type regula-
tion (fig. 4b). This case illustrates a general principle, whereby
the magnitude of drug resistance conferred by a change in
gene expression depends on two factors: First, the strength of
the gene’s influence on drug potency; and second, the degree
of nonoptimality of native expression under drug treatment.
For example, the overexpression of a particular gene could
confer a small increase in resistance when the gene is strongly
protective but only slightly nonoptimal, or also because the
gene is weakly protective but highly nonoptimal.
It is unclear what are the evolutionary, genetic, and bio-
chemical reasons underlying these widespread shortcomings
in responding to antibiotic stress, but they are likely to de-
pend on the regulatory context and the nature of the stress.
For example, in many bacterial species ampC is accompanied
by a transcriptional activator, ampR, which senses the effects
of beta-lactam treatment and induces ampC-mediated resis-
tance (Lindquist et al. 1989; Dietz et al. 1997). However E. coli
lacks ampR, and ampC expression instead serves to maintain
normal cell morphology (Bishop and Weiner 1993;
Henderson et al. 1997). Thus, whether a gene provides intrin-
sic or latent resistance can depend on the presence of regu-
lators in its genomic context. Because antibiotic molecules, by
their construction or natural selection, are unusually potent
microbial toxins, we speculate that the mar and sox systems
are poorly used under native regulation because such general-
purpose xenobiotic defense systems may be insufficiently sen-
sitive to respond to antibiotics at their generally low inhibi-
tory concentrations. There are also examples of more
elaborate reasons for nonoptimal gene expression: A drug
or drug mixture may induce serious physiological imbalances
between cellular components, outside the usual range of their
regulation (Bollenbach et al. 2009) or may even induce a
harmful regulatory response in drug resistance systems
(Palmer et al. 2010). Most simply though, nonoptimal expres-
sion under antibiotic stress may result from a lack of evolu-
tionary selection for adaptive responses to historically novel
stresses. It would be interesting to see whether the extent of
nonoptimal regulation varies across stresses and microbial
species, and whether optimality is improved when a species
responds to its natural stresses, particularly considering that
many antibiotics are produced in natural microbial
ecosystems.
The observation that specific resistance genes can be well
used under some but not other antibiotics complicates the
discovery of resistance genes by genetic screens:
Overexpression may not increase resistance if the gene is
already optimally induced by wild-type regulation (intrinsic
resistance scenario in fig. 5a), and similarly, deletion of a re-
sistance gene may not cause hypersensitivity if the gene is not
expressed under treatment. Furthermore, for methods that
seek to identify drug mechanism of action by identifying
resistance-conferring mutations, or changes in drug suscepti-
bility in the presence of engineered gene expression changes
(Giaever et al. 1999), the present results indicate that such
studies must be interpreted with caution for the possibly
confounding effects of nonoptimal gene expression.
Mutations that “optimize” capacity to survive antibiotic stress
may involve breaking regulatory systems that are optimized
for antibiotic-free growth, in order to massively overproduce
resistance-conferring genes or entirely lose expression of
susceptibility-conferring genes. As a consequence, the benefit
of such mutations may rarely outlast the temporary antibiotic
stress, leaving substantial fitness costs for growth in antibiotic-
free environments.
Every imperfection in physiological adaptation provides an
opportunity for evolutionary adaptation. Changes in gene
expression constitute a large mutational target for the evolu-
tion of resistance to specific stresses because copy number
alterations are abundant in bacterial populations (Andersson
and Hughes 2009) and stresses themselves can induce muta-
tions including copy number changes (Hastings et al. 2000;
Bjedov et al. 2003; Galhardo et al. 2007), and—crucially—
because gene expression is widely nonoptimal under stress,
creating many opportunities for improvement. Thus, while
bacteria can achieve antibiotic resistance by acquiring func-
tional mutations and specific resistance mechanisms, we find
that they can also draw on an unappreciatedly vast pool of
mutations that contextually improve gene expression and
activate latent defense mechanisms.
Materials and Methods
Strains and Media
All selection experiments and growth rate assays were per-
formed in M63 minimal medium (2 g l1 (NH4)2SO4, 13.6 g
l1 KH2PO4, 0.5 mg l
1 FeSO4•7H2O, adjusted to pH 7.0 with
KOH) supplemented with 0.2% glucose, 0.1% casamino acids,
1 mM MgSO4, and 0.5 mg l
1 thiamine.
Escherichia coli strain BW25113 is the host for the KEIO
gene deletion library (Datsenko and Wanner 2000; Baba et al.
2006). The strains of the KEIO gene deletion library (Baba et al.
2006) were grown individually in 384-well plates with 80ll of
Lysogeny broth per well, with incubation at 37 C and shaking
at 900 rpm for 24 h. All cultures were then collected in a single
beaker and mixed, passed through 5-lm cellulose acetate
filters to disrupt cell clumps, and frozen in aliquots at
80 C in 10% glycerol. As the ASKA open reading frame
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(ORF) library of plasmids was supplied in the AG1 cloning
strain (Kitagawa et al. 2005), the plasmids were purified and
transformed in pools into the “wild-type” strain MG1655
rphþ DlacIZYA (gift from K.E. Shearwin; constructed from
BW30270 [CGSC7925] by precise deletion of lacIZYA [EcoCyc
MG1655: 360527–366797] by recombineering) to minimize
artifacts arising from the poor health of the cloning strain.
The lacIZYA deletion engineered into this MG1655 strain
allows the use of IPTG to exclusively induce plasmid-based
expression without additional fitness effects due to induction
of the lac operon. No such alterations were required for the
deletion library as BW25113 has only minor perturbations
relative to wild-type MG1655, and IPTG was not required
to induce a change in gene expression. The AG1 strains of
the ASKA library were grown by the same protocol as de-
scribed for the KEIO library, and the chloramphenicol resis-
tance and ORF-encoding pCA24N plasmids were isolated as a
pooled mixture from each 384-well plate by a QIAGEN Spin
Miniprep kit. Plasmid pools were transformed into MG1655
rphþ DlacIZYA by the one-step protocol of reference (Chung
et al. 1989). To enrich for plasmid transformed cells, liquid
cultures of transformed E. coli (109 cfu) were inoculated
into 10 ml of M63 minimal medium with 30lg ml1 chlor-
amphenicol and were incubated overnight at 37 C with
shaking at 300 rpm. All transformant pools were added to a
single flask, mixed, and frozen in aliquots at 80 C in 10%
glycerol. Transforming the complete overexpression library
into a fresh background has the benefit that in the drug
diffusion screen, each ORF-expression plasmid is represented
in the zone of selection not by multiple descendants of a
common transformation event, but by descendants of
many transformation events (typically no more than one
descendant of each transformation within a 3-mm zone of
mutant selection), conferring confidence that resistance, if
observed in multiple colonies with the same plasmid, is con-
ferred by the plasmid rather than the background. A wild-
type reference for the ASKA library was constructed by trans-
forming MG1655 rphþ DlacIZYA with a pCA24N plasmid
encoding yellow fluorescent protein (yfp), but with the pro-
moter deleted (pCA24N-DpT5lac-yfp).
Growth rate assays in figures 3 and 4 were conducted in
BW25113 background; in these figures, “wild type” refers to
BW25113, “gene deletion” refers to the member of the KEIO
deletion library lacking the gene of interest (BW25113
gene::KanR), where the Kanamycin resistance cassette has
been excised by FLP recombinase from a temperature-
sensitive helper plasmid, yielding a strain BW25113
gene::FRT (Datsenko and Wanner 2000). Excision of kanamy-
cin resistance and loss of the helper plasmid, by colony puri-
fication at 43 C, were verified by testing for loss of antibiotic
resistances. Controlled gene expression was produced by
complementing a gene deletion strain with a pCA24N plas-
mid with IPTG-inducible expression of the deleted gene; these
plasmids were obtained from the ASKA library and the ORFs
were sequenced to confirm gene identity (Kitagawa et al.
2005). As lacIZYA is deleted in BW25113, IPTG does not incur
fitness costs for lac operon production (Stoebel et al. 2008),
and graded induction is possible without the LacY permease,
that would otherwise cause all-or-none induction of LacI-
regulated promoters (Novick and Weiner 1957; Choi et al.
2008). Regarding the drug diffusion assay (described below),
this removal of “all-or-none” induction is necessary for differ-
ent IPTG concentrations to induce different levels of gene
expression, rather than inducing different fractions of the
population to be “off” or “all on.” For consistency, both
wild type and gene deletion strains were transformed with
pCA24N-DpT5lac-yfp. All strains were then transformed with
plasmid pCSk which encodes a constitutively expressed bac-
terial bioluminescence operon (Kishony and Leibler 2003).
Drug solutions were made from powder stocks (from
Sigma Aldrich unless specified otherwise: amikacin, A1774;
ampicillin, A9518; azithromycin, Tocris 3771; bleomycin,
Selleck S1214; carbenicillin, C1613; cephalexin, C4895; cefox-
itin, C4786; cefsulodin, C8145; ciprofloxacin, 17850; chloram-
phenicol, C0378; clindamycin, Indofine C0117; colistin, C4461;
doxycycline, D9891; erythromycin, Fluka 45673; isopropyl b-D-
1-thiogalactopyranoside, Omega Bio-Tek AC121; kanamycin,
K1876; lomefloxacin, L2906; mecillinam, 33447; nalidixic acid,
N3143; nitrofurantoin, N7878; ortho-nitrophenyl-b-galacto-
side, N1127; penicillin G, Fluka 13750; phleomycin, P9564;
polymyxin-B, P0972; rifamycin SV, Biochemika 83909; spec-
tinomycin, S9007; spiramycin, S9132; streptomycin, S6501;
sulfacetamide, S8627; sulfamethoxazole, S7507; tetracycline,
87128; tobramycin, T4014; triclosan, TCI America T1872; tri-
methoprim, T7883; vancomycin, V8138). Drug and IPTG gra-
dients were made by serial dilution in M63 medium.
Pooled-Library Drug Diffusion Assay
Frozen aliquots of deletion library host (BW25113), or pooled
deletion library, or overexpression library host (MG1655 rphþ
DlacIZYA pCA24N-DpT5lac-yfp), or pooled overexpression
library, were thawed, and 107 cells were spread by glass beads
on wet 10-cm Petri dishes containing 25 ml of 1.5% agar M63
minimal media; with 15 or 150lM IPTG only when plating
the pooled overexpression library. Based on the typical sizes of
zones of mutant selection (a 3-mm annulus at diameter of
30 mm  200-mm2 area), and the inoculum, we calculate
that each gene expression mutant is typically represented by
up to 100 colonies in the zone of mutant selection (depend-
ing on how far past the edge of the zone of inhibition they
grow); therefore, this inoculum provides each expression mu-
tant with a chance of identification if it confers drug resis-
tance. Plates were briefly dried in a biosafety cabinet before an
aliquot of antibiotic was pipetted in the center of the plate.
Supplementary table S5, Supplementary Material online, lists
the concentrations and volumes of each antibiotic solution
used in this assay. Plates were incubated at 37 C for 48 h
before being photographed by a custom plate imager (Chait
et al. 2010). Plates treated with sulfacetamide and sulfameth-
oxazole were instead incubated for 1 week due to the slow
growth of drug-resistant colonies (these grow at usual speed
when transferred onto drug-free agar); in all other drugs, re-
sistant colonies either appeared within 48 h or were not ap-
parent even after 1 week. Up to 48 drug-resistant colonies per
plate (not including wild-type reference plates) were viewed
in a Nikon SMZ-745T stereomicroscope, picked by a flame-
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sterilized 0.25-mm nichrome wire, and streaked on selective
agar: 50lg ml1 of kanamycin for the gene deletion library
and 30lg ml1 of chloramphenicol for the gene overexpres-
sion library. Streaked plates were incubated at room temper-
ature for several days, a single colony from each plate was
inoculated into a liquid culture of selective Lysogeny broth in
a 96-well microtiter plate. Microtiter plates were incubated
overnight at 37 C with shaking at 900 rpm, and glycerol was
added to each well to a final concentration of 15%.
Microtiter plates were stored frozen at 80 C. Genes in
the overexpression library that confer drug resistance were
identified by sending bacterial cultures to GENEWIZ to
Sanger sequence the ORF of the pCA24N plasmid using
the primer ASKAseqLF (CACCATCACCATCACCATACG).
Gene deletions in the KEIO library that confer drug resis-
tance were identified by Sanger sequencing the products
of a 2-step hemi-nested polymerase chain reaction (PCR)
that amplified a portion of chromosome adjacent to the
Kanamycin resistance cassette that replaces each deleted
gene. Both PCR steps used 20-ll reactions with 2 units of
OneTaq DNA Polymerase (New England Biolabs M0480),
200 nM of each primer (Integrated DNA Technologies),
and 200 lM of each dNTP (New England Biolabs N0447).
The first PCR was inoculated with 1 ll of liquid bacterial
culture, and used the three primers KEIOseq1
(TGAAGTTCCTATTCCGAAGTTCCTATTCTC), CEKG2C
(GGCCACGCGTCGACTAGTACNNNNNNNNNNGATAT),
and CEKG2D (GGCCACGCGTCGACTAGTACNNNNNN
NNNNACGC) in the following reaction cycle: First 50 at
95 C; 6 cycles of 3000 at 95 C, 3000 at 42 C (lowering by
1 C per cycle), 30 at 68 C; then 24 cycles of 3000 at 95 C,
3000 at 45 C, 30 at 68 C; and finally 50 at 68 C. The second
PCR was inoculated with 0.5ll per well of the completed
first PCR, and used the primers KEIOseq3 (TCGAAGCAGC
TCCAGCCTAC) and CEKG4 (GGCCACGCGTCGACTAGT
AC) in the following reaction cycle: 30 cycles of 3000 at
95 C, 3000 at 56 C, 30 at 68 C; and finally 50 at 68 C.
Products of this final PCR were sent to GENEWIZ for se-
quencing by the KEIOseq3 primer. Sequences were aligned
with BlastN to the E. coli MG1655 genome (NC_000913.2)
to determine gene identity (Altschul et al. 1990; Blattner
et al. 1997). Alignments that started more than 100 nucleo-
tides from the expected start of alignment were discarded:
Gene overexpression sequences should align shortly after
the start codon of an ORF; gene deletion sequences should
align shortly after the stop codon of an ORF.
Drug Diffusion Assay Secondary Validation
Single mutant strains (gene deletion or gene overexpression)
were inoculated at 1:500 frequency into the matching wild-
type strain (for gene deletion, BW25113; for gene overexpres-
sion, MG1655 rphþ DlacIZYA pCA24N-DpT5lac-yfp). Each
mixed culture of wild type and mutant was plated on a
Petri dish and treated with a diffusing point source of antibi-
otic, precisely as performed in the primary screen. From each
plate, four drug-resistant colonies growing inside the zone of
inhibition were picked with a flame-sterilized 0.25-mm ni-
chrome wire, and streaked onto selective agar. Gene deletion
mutants were tested by streaking resistant colonies onto
Kanamycin, on which only the gene deletion mutants are
proficient for growth, because wild-type BW25113 is not
Kanamycin resistant. Therefore, growth or no-growth on
Kanamycin was sufficient to identify when selected colonies
were the “spike-in” gene deletion mutant or the wild type.
Gene overexpression mutants were streaked onto
Chloramphenicol, on which both wild type and mutants
are proficient for growth. Restreaked colonies were tested
by colony PCR, inoculating a small quantity of colony into
a reaction that amplifies the promoter present in the ORF-
expressing plasmids, and not the control plasmid present in
wild-type reference wherein the promoter had been deleted.
Primers were ATTTGCTTTGTGAGCGGATAAC and
ATCAACAGGAGTCCAAGCTCAG, used with the following
reaction: 30 cycles of 3000 at 95 C, 3000 at 51 C, 6000 at 68 C;
and finally 50 at 68 C. Reaction products were visualized by
agarose gel electrophoresis to distinguished wild-type colo-
nies from ORF-expressing colonies.
Growth Rate Assay
Bacterial growth rates were measured by bioluminescence
precisely as described by Palmer and Kishony (2014).
Notably, the pCSk plasmid confers constitutive biolumines-
cence that allows cell densities in growing cultures to be
precisely measured over many orders of magnitude by pho-
ton counting (Kishony and Leibler 2003). Growth rate is thus
taken from the steepest slope of the logarithm of photon
counts over a 6-h time span of constant growth, correspond-
ing to five doublings in a healthy culture. The slope of the
logarithm of photon counts is unaffected by changes in lu-
minescence per cell, such as might result from antibiotic
treatments or changes in gene expression (Kishony and
Leibler 2003). Note that because the small inoculum causes
growth to enter the measurable regime only after several
hours of growth, and because the sensitivity of the method
allows growth to be measured over many hours of exponen-
tial growth, it is improbable that transient kinetics of induc-
tion following first exposure to IPTG should influence steady-
state growth rates. The IPTG-inducible gene expression
system utilized in these experiments (figs. 3 and 4) has pre-
viously been characterized under partially inhibitory doses of
several mechanistically distinct antibiotics, and it was found
to be robust to antibiotic perturbation (Palmer and Kishony
2014). Specifically, the quantitative relationship between IPTG
and the activity of a LacZ reporter gene was not substantially
altered by antibiotic inhibition of growth to the range of
50–80% of uninhibited growth, with the exception of a cell
wall antibiotic (mecillinam) under which IPTG appeared to
enter the cell more readily. In figure 3a the growth trend line
is a B-spline, and in figure 3b experimentally measured points
are connected by straight lines.
Beta-Galactosidase Assay
Kinetic beta-galactosidase (LacZ) assays were performed pre-
cisely as described by Palmer and Kishony (2014), taking 20ll
of culture for lysis and assay.
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